Eos Energy stock falls after Fuzzy Panda issues short report
Investing.com - Guggenheim upgraded Neumora Therapeutics (NASDAQ:NMRA) from Neutral to Buy on Monday, setting a price target of $14.00 following promising preclinical obesity data and positive Phase II results for VTX-3232. The stock, currently trading at $2.63, has shown significant volatility with a 128% surge over the past six months, according to InvestingPro data.
The upgrade centers on Neumora’s NLRP3 inhibitor program targeting obesity and cardiometabolic disorders, which Guggenheim now views as a clear driver for value creation. The firm cited compelling data from diet-induced obesity mouse models showing potential for metabolic efficacy in humans. InvestingPro analysis shows the company maintains a strong liquidity position with a current ratio of 10.54, though it’s currently experiencing rapid cash burn.
Guggenheim projects approximately $3 billion in global peak sales for Neumora’s obesity treatment if approved. The firm also highlighted potential synergy with GLP-1 drugs, noting Neumora’s preclinical data suggests its treatments could complement incretin therapies by addressing cardiovascular and hepatic inflammation while potentially enhancing weight loss.
The research note pointed to recently de-risked cardiovascular indications that provide a solid alternative path for Neumora’s pipeline. Additional value drivers include CNS NLRP-3 inhibition for neurological conditions like Parkinson’s disease, the ’511 program in ADA, and the M4 franchise in schizophrenia.
Neumora will present additional data during its virtual R&D day Monday at 8:00am ET, with Guggenheim expecting investor interest to build steadily over the upcoming months based on the obesity program’s translational signals, validated cardiovascular risk reduction pathway, and multiple near-term catalysts.
In other recent news, Neumora Therapeutics reported second-quarter 2025 earnings that exceeded analyst expectations, with an earnings per share (EPS) of -$0.33 compared to the forecasted -$0.45. The company has also initiated a Phase 1 study for NMRA-898, the second compound in its M4 muscarinic receptor positive allosteric modulator franchise, aimed at treating schizophrenia and other neuropsychiatric disorders. Additionally, Neumora announced promising preclinical results for its obesity treatment NMRA-215, which demonstrated significant weight loss in mouse models. H.C. Wainwright maintained its Buy rating on Neumora, with an $18.00 price target, ahead of the company’s virtual analyst meeting focusing on NMRA-215. Meanwhile, Stifel reiterated its Hold rating with a $2.00 price target, noting the company’s strategic adjustments following a previous trial failure. Neumora’s ongoing clinical trials and strong cash position provide a foundation for future developments. These recent updates reflect Neumora’s active progress in its research and development initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.